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Abstract Expression of the early genes of the human immuno- 
deficiency virus type-1 (HIV-1) genome is under the control of a 
trans-activator (Tat) protein. H1V-1 Tat action requires binding 
to TAR (trans-activation responsive lement), an RNA sequence 
located at the 5'-end of all lentiviral mRNAs. We used various 
spectroscopic methods to investigate conformational changes on 
HIV-1 TAR binding to the HIV-1 (32-72) Tat peptide BP1. It 
comprises the RNA binding region and binds specifically to TAR. 
We conclude from our experiments that the regular A-form of 
the TAR RNA is slightly distorted towards the B-form when 
bound to BPI. Thus, the major groove is widened and the binding 
of BP1 facilitated. BP1 presumably adopts an extended 
conformation when binding to TAR and may fit well into the 
TAR major groove. 
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1. Introduction 
The Tat (trans-activating) protein activates and enhances 
DNA transcription by binding to a particular sequence of 
nascent mRNA,  the TAR (trans-activation response lement) 
element. Tat is a key regulatory protein as it enhances the 
expression of all viral genes, and the virus is not able to 
replicate in the absence of Tat. Tat binds to the uridine-rich 
bulge of TAR [14] and the core and the basic region of Tat 
are the key elements for specific recognition of TAR [5-10]. 
Structural studies of the Tat TAR interaction have shown 
conformational changes in TAR on binding of various Tat 
peptides [11-14]. The extent to which the recognition region 
of HIV-1 Tat undergoes conformational changes when bound 
to TAR RNA is still unknown. For the bovine imrnunodefi- 
ciency virus (BIV) conformational changes occur in both the 
TAR RNA and the Tat peptide when they form a complex 
[15,16]. To gain more insight into the nature of conforma- 
tional changes of HIV-1 Tat and TAR on complex formation 
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we investigated a model of the complex by circular dichroism 
(CD), Fourier transform infrared (FTIR) and UV-melting 
studies. We used a 29-mer HIV-1 TAR RNA and the HIV- 
1 Tat peptide fragment BP1 which comprises the whole wild- 
type core and basic sequence regions of Tat, amino acids 32 to 
72, that are sufficient for strong and specific binding to TAR 
[6]. 
2. Materials and methods 
2.1. Sample preparation 
The 29-nucleotide HIV-1 TAR RNA was synthesized by in vitro 
transcription using T7 RNA polymerase and synthetic DNA tem- 
plates (MWG-BioTech, Ebersberg) [17]. TAR RNA was ethanol pre- 
cipitated and purified by 20% polyacrylamide g l eletrophoresis under 
denaturing conditions (8.3 M urea). TAR RNA product was eluted 
from the gel by using a Schleicher and Schuell electroelution appara- 
tus and subsequent ethanol precipitation. The RNA was dialysed to 
remove multivalent ions and other low molecular weight impurities 
against a high EDTA buffer (10 mM phosphate, 5 mM EDTA, 100 
mM NaC1, pH 6.4), a low EDTA buffer (10 mM phosphate, 0.1 mM 
EDTA, 100 mM NaCI, pH 6.4), and finally against water. TAR RNA 
was then lyophilized and stored at -20°C. Several reactions on a 5 ml 
scale yielded more than 20 mg of purified RNA. 
BP1 was synthesized on an automated continuous-flow peptide 
synthesizer on polystyrene-polyethylene glycol copolymer (Tentagel) 
using 9-fluorenylmethyloxycarbonyl chemistry and (benzotriazo-l-yl)- 
N-oxytripyrrolidinophosphonium hexafluorophosphate as activator 
[18]. The product was purified by reversed-phase high-performance 
liquid chromatography (HPLC) to more than 95% purity based on 
mass spectroscopic analysis (Shimadzu Compact MALDI). The syn- 
thetic peptide was freeze-dried and stored at -20°C. 
2.2. Thermodynamic analysis 
Equilibrium melting curves were collected on a Hewlett-Packard 
8452A diode array spectrophotometer equipped with a Peltier element 
and a temperature sensor inserted into the 1 cm cell. Before each 
measurement the RNA component (2 ~tM) was renatured by heating 
to 90°C for 3 min followed by slow cooling to room temperature in 10 
mM potassium phosphate, 50 mM NaC1, pH 6.4. The molar ratio of 
BP1 HIV-1 and TAR was 1:1, and of argininamide to HIV-1 TAR 
RNA, 6:1. Samples were heated at a rate of 0.4°C per min. Spectra 
from 235 nm to 350 nm were recorded at intervals of I°C. Reversi- 
bility of the melting process was examined by cooling to the initial 
temperature. Thermal denaturation curves were followed by the in- 
crease of absorbance at 260 nm. The midpoints of the melting transi- 
tions, Tin, were determined as described [19]. 
2.3. FTIR spectroscopy 
FTIR spectra were obtained with a Bruker IFS 66v Fourier trans- 
form IR spectrometer. 200 scans were collected and Fourier trans- 
formed to obtain spectra with 2 cm -1 resolution. All measurements 
were performed in a CaF2 cell with 25 ~tM pathlength at room tem- 
perature. Spectra were obtained for the HIV-1 TAR alone (0.3 mM) 
and for the BP1-HIV-1 TAR complex at 1:1 molar ratio (0.3 mM) in 
a solution containing 10 mM potassium phosphate, 50 mM NaC1 at 
pH 6.4. 
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2.4. CD spectroscopy 
CD spectra were measured with a Jasco J600A spectropolarimeter 
in thermostatically controlled cells at 25°C. The buffer was 10 mM 
potassium phosphate, 50 mM NaC1 at pH 6.4. Concentrations of the 
HIV-1 TAR and of the 1:1 BP1-HIV-1 TAR complex were 30 ~tM in 
a 0.05 cm cell. The reference sample contained buffer without RNA 
and/or peptide, and spectra were measured three times at a scan rate 
of 20 nm/min, averaged and corrected for contributions of the respec- 
tive solvent. 
2.5. Secondary-structure prediction 
Secondary-structure pr dictions were performed by the methods of 
Gibrat et al. [20], Levin et al. [21] and Deleage and Roux [22] as 
supplied by the mail server of the Institute de Biologie et Chimie 
des Proteines (Lyon) and by the PHD neural network structure pre- 
diction method [23] as obtained via the European Molecular Biology 
Laboratory (EMBL) mail server. 
3.  Resu l ts  
3.1, UV melting 
To determine the conformational stability of the hairpin 
structure of HIV-1 TAR thermal melting experiments were 
carried out with and without specific and unspecific ligands. 
Binding of BP1 to TAR enhanced significantly the thermo- 
stability of HIV-1 TAR. In the presence of the peptide, the 
midpoint of the thermal transition (Tm) of the RNA increased 
from 65°C for the unbound HIV-1 TAR to 71°C (Fig. 1). To 
confirm that this is a specific effect of the BP1 peptide, in a 
control experiment argininamide was added at a 6-fold molar 
excess. Argininamide binds to HIV-1 TAR in a rather non- 
specific manner [6] and left the thermal unfolding transition of 
TAR virtually unchanged (Fig. 2). Although the free peptide 
is unstructured in solution (as indicated by CD experiments, 
see below) the increased thermostability suggests the forma- 
tion of a specific RNA peptide complex with a high stability 
over a wide temperature range. Stabilizing effects on their 
nucleic acid target were previously reported for some polypep- 
tides [24,25]. 
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Fig. 1. Melting curves of HIV-1 TAR (O, right vertical scale) and 
the BP1-TAR RNA complex at 1:1 molar ratio (O, left vertical 
scale) as monitored by the absorbance at 260 nm. Measurements 
were made in 10 mM potassium phosphate, 50 mM NaCI (pH 6.4). 
The BP1 and the TAR RNA concentrations were 2 ~tM. 
A.U. Metzger et al./FEBS Letters 384 (1996) 255-259 
E 
c- 
O 
0 
el" 
£ 
0 
W 
e~ 
< 
0.19 
0.18 
0.17 
0.16 
0.2 
0.19 
0.18 
0.17 
i i i i 
20 40 60 80 
Temperature (*C) 
Fig. 2. UV absorbance melting curves of HIV-1 TAR (O, left verti- 
cal scale) and the argininamide-TAR RNA complex at 6:1 stoichio- 
metric ratio (e, right vertical scale). Measurements were made in 10 
mM potassium phosphate, 50 mM NaC1 (pH 6.4). The TAR RNA 
and the argininamide concentrations were 2 and 12 I.tM, respec- 
tively. 
3.2. FT IR  spectroscopy 
For free TAR an absorbance maximum at 1243 cm -1 was 
observed, characteristic of the antisymmetric O-P-O phos- 
phate stretching vibration in the sugar phosphate backbone 
of RNA in the regular A-form helix. This band shifted to 
1223 cm -1 on addition of BP1 (Fig. 3), indicating a confor- 
mational change in the RNA backbone and involvement of 
the phosphates in the interaction with the BP1 peptide [26,27]. 
No major peptide signals contribute significantly to intensity 
in this spectral region [44]. The change of the positions of the 
absorption maxima suggests a distortion of the A-helix (1243 
cm -1) towards a B-helix (1223 cm -1)  [27] as well as the for- 
mation of hydrogen bonds or ionic contacts between phos- 
phates and peptide. This could imply that the narrow major 
groove as found in a regular A-helix and in free TAR may be 
widened on peptide binding which is consistent with the re- 
suits of recent NMR studies by Varani and co-workers on 
HIV-1 TAR complexed by a similar peptide [14]. They 
showed that peptide binding induced a conformational tera- 
tion in TAR which enhanced the accessibility of functionally 
important groups in the major groove near the RNA bulge. 
3.3. CD spectroscopy 
The CD spectrum of TAR alone is characteristic of an A- 
form RNA with a long-wavelength band centred around 265 
nm and a fairly intense negative band around 210 nm (Fig. 4). 
The strong RNA signals dominate the CD spectrum of the 
BP1 TAR complex. The shapes of both CD spectra are very 
similar suggesting that the overall conformation of TAR is in 
the A-form in the complex with BP1. An increase in the in- 
tensity of the 240-nm band, a decrease as well as a red shift of 
the 265-nm band, and a red shift of the crossover from 239 
nm to 241 nm indicate a marginal distortion of the A-form 
helix towards the B-form [13]. Between 240 and 300 nm no 
contribution of the peptide CD spectrum is expected, ensuring 
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Fig. 3. Direct FTIR solution spectra of HIV-1 TAR and the BP1- 
TAR RNA complex at 1:1 molar ratio in 10 mM potassium phos- 
phate, 50 mM NaC1 (pH 6.4) at 25°C. The concentrations of the 
RNA and peptide were 0.3 mM. 
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Fig. 4. UV-CD spectra of HIV-1 TAR (broken line) and the BP1- 
TAR RNA complex at 1:1 molar ratio (solid line) in 10 mM potas- 
sium phosphate, 50 mM NaCI (pH 6.4) at 25°C. The concentrations 
of the RNA and peptide were 30 I.tM in 0.05 cm cells. The MRW 
normalisation of the ellipticity is not possible in this case, since one 
of the samples i heterogeneous. 
that the observed changes originate xclusively from the RNA 
[28]. TAR was previously suggested to adopt B-helix charac- 
ter on binding of smaller Tat-related peptides [13], in agree- 
ment with FTIR results. The CD spectrum of free BP1 (Fig. 
5) with its minimum near 200 nm shows that BP1 is in an 
unfolded conformation, consistent with NMR data (Bayer et 
al., unpublished data). As the TAR spectrum was only mar- 
ginally distorted on TAR binding to Tat, the difference-CD 
spectrum derived from the TAR-BP1 complex and free TAR 
(Fig. 5) should provide a rough guess of the CD spectrum of 
the bound peptide, and previous tudies how that difference- 
CD spectra re well suited to predict he secondary structures 
correctly [15,16,29]. According to this procedure, the mini- 
mum of molar ellipticity is shifted to 217 nm, an effect typical 
of polypeptides adopting extended conformations, such as 13- 
strands [28]. As TAR may also contribute to this far-UV 
region, the extended conformation of bound BP1 cannot be 
determined safely from this approach. Summarizing, FTIR 
and CD results would be in agreement with the notion of 
BP1 adopting an extended conformation on binding in the 
widened major groove of TAR. 
3.4. Secondary structure prediction 
To investigate the conformation preference of the amino 
acid sequence we performed secondary structure predictions 
using standard protocols. Fig. 6 shows clearly that all these 
protocols predict a I]-type conformation for the core sequence 
of BP1, in agreement with BP1 adopting an extended confor- 
mation in this region, as observed by the CD studies on the 
BP1-TAR complex. 
4. Discussion 
The present results uggest that the interaction of BP1 pep- 
tide with HIV-1 TAR RNA involves noticeable conforma- 
tional changes of both components, as observed earlier for 
other protein-nucleic a id interactions [30-32]. BP1 comprises 
the highly flexible basic region and the adjacent compact core 
sequence region of the full-length HIV-1 Tat protein [33]. In 
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Fig. 5. Far-UV CD spectrum of the BP1 peptide (broken line) and 
the difference CD spectrum of the BP1-TAR RNA complex minus 
HIV-1 TAR (solid line) in 10 mM potassium phosphate, 50 mM 
NaC1 (pH 6.4) at 25°C. 
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Fig. 6. Secondary structure predictions of BP1 peptide. H, s-helix; 
E sheet; T, turn. Core sequence region is underlined. 
the free form it is in an unfolded conformation. When bound 
to TAR, the peptide, however, exhibits a CD spectrum sug- 
gesting an extended conformation as in [5-sheets. This is in 
good agreement with the results of several sequence based 
secondary structure predictions, but in contrast to previous 
structural studies on various Tat peptide-TAR systems that 
suggested helical tendencies of the basic sequence region alone 
or on RNA binding [13,34]. In an NMR study of an EIAV- 
HIV-1 Tat chimeric peptide comprising the core sequence re- 
gion of EIAV Tat and the basic region of HIV-1 Tat, a high 
c~-helix content in the basic region of the chimeric peptide was 
observed [34]. The EIAV core sequence region, however, has 
some intrinsic potential for helix formation [35,36]. Thus, the 
chimeric peptide may exhibit a higher tendency to form an cx- 
helix than a peptide with the HIV-1 Tat wild type sequence. 
Tat and TAR interaction occurs in the deep A-form major 
groove of the RNA near the bulge [6,7]. Even a slightly wi- 
dened major groove of the HIV-1 TAR, however, would be 
too narrow to accommodate an a-helical peptide [37,38]. 
Extended conformations are found at the recognition sites 
of both DNA minor groove binding proteins (TATA-box 
binding protein) [39,40] and RNA binding proteins 
[37,41,42] when steric requirements render the formation of 
co-helices disadvantageous. The DNA minor groove has a 
geometry comparable to that of the A-form RNA major 
groove. 
CD and FTIR measurements suggest a minimal transition 
from the A to B form of TAR on peptide binding as well as 
an involvement of backbone phosphates in the interaction 
with BP1 as originally proposed [6,7,43]. In agreement with 
this observation, Varani and co-workers [14] showed that free 
TAR contains a large degree of helical discontinuity, leading 
to a more accessible major groove that forms the contact area 
with the peptide. The structure of the BIV TAR Tat peptide 
complex shows that the peptide containing the basic sequence 
region of the BIV Tat protein adopts a I~-turn conformation 
and also binds to the widened major groove of the BIV TAR 
RNA [15,16]. The experimental results on Tat-TAR interac- 
tions for BIV and HIV-1 thus seem to become more consis- 
tent, and a fuller picture emerges. 
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